dna
vaccin
evolv
greatli
last
year
sinc
invent
yet
becom
competit
altern
convent
protein
carbohydr
base
human
vaccin
whilst
safeti
concern
initi
barrier
achil
heel
dna
vaccin
remain
poor
immunogen
compar
protein
vaccin
wide
varieti
strategi
develop
optim
dna
vaccin
immunogen
includ
codon
optim
genet
adjuv
electropor
sophist
primeboost
regimen
method
advantag
limit
whilst
method
contribut
increment
improv
dna
vaccin
efficaci
still
need
human
dna
vaccin
succeed
commerci
review
forese
final
breakthrough
human
dna
vaccin
come
applic
latest
cuttingedg
technolog
includ
epigenet
omic
approach
alongsid
tradit
techniqu
improv
immunogen
adjuv
electropor
therebi
overcom
current
limit
dna
vaccin
human
unlik
convent
protein
polysaccharid
base
vaccin
dna
vaccin
compris
plasmid
encod
vaccin
antigen
along
strong
eukaryot
promot
use
drive
protein
express
rajcani
et
al
nucleic
acid
base
vaccin
deliv
intramuscularli
subcutan
mucos
aim
gain
access
cell
cytoplasm
therebi
induc
antigen
express
vivo
like
protein
vaccin
mimic
elicit
desir
immun
respons
dna
vaccin
success
appli
anim
model
various
prevent
treat
infecti
diseas
cancer
autoimmun
allergi
ulmer
et
al
posit
side
straightforward
plasmid
structur
dna
vaccin
give
inher
advantag
tradit
protein
carbohydr
base
vaccin
onestep
clone
target
code
sequenc
plasmid
vector
offer
conveni
develop
product
compar
cultur
inactiv
whole
infecti
pathogen
express
purif
recombin
protein
furthermor
induc
express
protein
vivo
antigen
structur
like
resembl
nativ
protein
structur
includ
essenti
posttransl
modif
safeti
perspect
amplif
nucleic
acid
encod
potenti
antigen
avoid
need
directli
handl
danger
pathogen
conveni
manipul
plasmid
dna
vitro
allow
easi
introduct
benefici
mutat
antigen
code
sequenc
vitro
mutat
also
enabl
modif
antigen
code
sequenc
counter
rapidli
drift
viru
strain
plasmid
dna
stabl
room
temperatur
allow
conveni
storag
ship
addit
physic
properti
dna
vaccin
enabl
express
antigen
present
mhc
class
class
ii
complex
therebi
stimul
cell
addit
b
cell
date
veterinari
dna
vaccin
approv
use
fish
infecti
haematopoiet
necrosi
viru
dog
melanoma
swine
growth
hormon
releas
hormon
hors
west
nile
viru
kutzler
weiner
howev
success
veterinari
approv
translat
success
human
dna
vaccin
applic
low
immunogen
remain
achil
heel
human
dna
vaccin
recent
year
mani
clinic
trial
undertaken
dna
vaccin
cover
full
rang
prophylact
therapeut
vaccin
vaccin
infect
cancer
rang
disord
detail
studi
avail
rang
websit
includ
http
wwwcancergov
clinicaltri
http
clinicaltrialsgov
http
clinicaltrialsfeedsorg
http
wwwdnavaccinecom
http
wwwniaidnihgovvolunteervrcpagesdefaultaspx
howev
despit
clinic
trial
work
still
clearli
requir
design
deliveri
lift
immunogen
dna
vaccin
level
requir
human
regulatori
approv
commerci
exploit
wolff
et
al
show
inject
dna
encod
lactas
report
gene
mous
quadricep
muscl
induc
sustain
protein
express
wolff
et
al
tang
et
al
subsequ
show
introduc
plasmid
encod
human
growth
hormon
hgh
mous
skin
induc
antibodi
respons
express
protein
tang
et
al
therebi
directli
mimick
protein
vaccin
final
proof
dna
encod
antigen
could
provid
effect
vaccin
protect
came
demonstr
inject
plasmid
encod
influenza
nuclear
protein
mous
muscl
gener
influenzaspecif
cytotox
lymphocyt
ctl
protect
mice
subsequ
influenza
challeng
ulmer
et
al
whilst
studi
confirm
theoret
util
dna
vaccin
practic
consider
remain
exampl
dna
inocul
result
antigen
express
low
picogram
nanogram
rang
transfect
somat
cell
profession
antigen
present
cell
apc
potenti
offset
sustain
low
level
antigen
express
achiev
inject
dna
may
better
prime
adapt
immun
respons
compar
short
halflif
inject
protein
antigen
least
three
differ
mechan
propos
contribut
immunogen
dna
vaccin
dnaencod
antigen
present
somat
cell
myocyt
keratinocyt
mhc
class
pathway
cell
dna
immun
result
direct
transfect
profession
antigen
present
cell
apc
eg
dendrit
cell
crossprim
result
transfect
somat
cell
phagocytos
profession
apc
present
antigen
cell
muscl
cell
effici
present
antigen
via
mhc
class
latter
two
mechan
may
import
dna
vaccin
immunostimulatori
element
plasmid
dna
unmethyl
cpg
motif
may
also
make
contribut
dna
immunogen
cpg
dinucleotid
motif
low
frequenc
mostli
methyl
mammalian
genom
contrast
bacteri
dna
contain
mani
unmethyl
cpg
motif
enabl
motif
recognis
mammal
pathogen
associ
molecular
pattern
pamp
unmethyl
cpg
activ
innat
immun
cell
bind
tolllik
receptor
tlr
hemmi
et
al
klinman
et
al
shown
import
effect
dna
vaccin
lymphocyt
choriomening
viru
lcmv
prime
boost
context
rottembourg
et
al
dendrit
cell
dc
requir
effici
prime
cell
upon
plasmid
exposur
vitro
singledos
vaccin
vivo
howev
mice
still
respond
dna
suggest
cpg
motif
essenti
dna
vaccin
action
babiuk
et
al
tudor
et
al
anoth
studi
show
tankbind
kinas
noncanon
kinas
mediat
adjuv
effect
dna
vaccin
mice
ishii
et
al
known
phosphoryl
activ
type
interferon
gene
transcript
sharma
et
al
furthermor
cytoplasm
dna
also
activ
absent
melanoma
sting
stimul
ifn
gene
innat
immun
pathway
barber
rathinam
et
al
stetson
medzhitov
may
therefor
also
contribut
dna
vaccin
action
current
propos
mechan
dna
vaccin
summar
figur
last
twenti
year
differ
method
develop
list
tabl
increas
efficaci
dna
vaccin
includ
discuss
codon
optim
altern
promot
plasmid
backbon
refin
inclus
antigen
subcellular
target
system
genet
adjuv
codon
usag
pathogen
often
quit
differ
mammalian
genom
antigen
code
sequenc
may
need
optim
effici
express
host
cell
earli
studi
dna
vaccin
encod
epitop
listeriolysin
llo
l
monocytogen
show
balbc
mice
codon
optim
improv
cell
respons
intracellular
bacterium
uchijima
et
al
codon
optim
dna
encod
bacteri
botulinum
neurotoxin
markedli
increas
neutral
antibodi
titer
mous
model
trollet
et
al
likewis
codon
optim
shown
increas
immunogen
provid
better
protect
challeng
dna
vaccin
schistosoma
japonicum
influenza
viru
hiv
hpv
rsv
siv
mous
model
cheung
et
al
lin
et
al
megati
et
al
ngumbela
et
al
siegismund
et
al
tenbusch
et
al
ternett
et
al
autom
algorithm
calcul
codon
optim
avail
assist
vaccin
develop
harish
et
al
sandhu
et
al
codon
optim
increas
antigen
express
may
per
se
alway
increas
vaccin
efficaci
exampl
malaria
dna
vaccin
studi
show
robust
cell
respons
protect
p
yoelii
sporozoit
challeng
nativ
rather
codonoptim
plasmid
mice
dobano
et
al
anoth
studi
mice
use
codonoptim
plasmid
encod
antigen
schistosoma
mansoni
found
codon
optim
increas
express
enhanc
immun
protect
mansoni
challeng
varaldo
et
al
reason
discrep
known
code
sequenc
dna
vaccin
driven
polymeras
ii
type
promot
endogen
mammalian
promot
gener
strong
enough
drive
high
level
antigen
express
strong
virusderiv
promot
like
cytomegaloviru
cmv
promot
vector
use
includ
pci
pcmv
earli
studi
show
cmv
immedi
earli
enhancerpromot
activ
consist
strongest
explain
widespread
usag
dna
vaccin
cheng
et
al
manthorp
et
al
intron
cmv
immediateearli
gene
often
includ
complet
cmv
promot
studi
show
secret
glycoprotein
significantli
higher
cell
transfect
intron
acontain
plasmid
chapman
et
al
studi
env
dna
vaccin
show
strong
promot
play
import
role
increas
antigen
express
therebi
vaccin
immunogen
mice
wang
et
al
howev
case
strong
promot
activ
problem
dna
vaccin
design
exampl
hepat
c
viru
hcv
core
protein
candid
vaccin
antigen
immunosuppress
properti
overcom
problem
hepat
c
viru
hcv
dna
vaccin
util
induc
vivo
activ
salmonella
promot
drive
core
protein
express
along
cmv
promot
drive
envelop
protein
express
way
immun
respons
gener
induc
hcv
core
protein
balbc
mice
howev
studi
shown
potenc
viral
promot
necessarili
correl
dna
vaccin
efficaci
may
induct
potent
dna
vaccin
paradox
downregul
viral
promot
therebi
reduc
immun
respons
vaccin
gribaudo
et
al
kerr
stark
vanniasinkam
et
al
xiang
ertl
nonvir
promot
mhc
class
ii
promot
also
shown
effect
dna
vaccin
mice
vanniasinkam
et
al
thu
although
cmv
promot
remain
first
choic
case
altern
promot
may
achiev
better
immunogen
dna
vaccin
current
use
dna
plasmid
compos
bacteriaderiv
sequenc
provid
replic
signal
select
marker
necessari
propag
differ
e
coli
strain
materi
may
pose
safeti
issu
could
neg
impact
mammalian
gene
express
bacteri
element
exampl
express
vector
wide
use
dna
vaccin
modifi
gener
new
gener
vector
order
reduc
redund
sequenc
chang
ampicillin
select
marker
kanamycin
given
potenti
ampicillin
trigger
allergi
reduc
size
vector
permit
clone
larger
dna
fragment
yet
retain
compar
antigen
express
level
anteced
vector
advantag
demonstr
fact
induc
autoimmun
inocul
mice
zhou
et
al
sucros
select
system
recent
develop
remov
need
antibiot
select
marker
vector
express
rnaout
antisens
rna
repress
express
chromosomallyintegr
constitutivelyexpress
counterselect
marker
sacb
allow
plasmid
select
sucros
luke
et
al
use
antibioticfre
system
base
pair
enhanc
incorpor
upstream
cmv
promot
increas
extrachromosom
transgen
express
human
tlymphotrop
viru
type
htlvi
r
region
downstream
cmv
promot
increas
mrna
translat
effici
increas
dna
vaccineinduc
neutral
antibodi
titer
demonstr
rabbit
use
vector
system
luke
et
al
minicircl
dna
mcdna
technolog
develop
complet
remov
bacteri
backbon
use
sitespecif
recombin
base
para
resolvas
gener
mcdna
jechling
et
al
anoth
method
mcdna
product
use
genet
modifi
e
coli
construct
produc
strain
stabli
express
set
induc
minicircleassembl
enzym
integras
iscei
home
endonucleas
kay
et
al
mcdna
technolog
success
use
gene
therapi
experi
mous
model
osborn
et
al
zuo
et
al
gener
adult
human
induc
pluripot
stem
cell
narsinh
et
al
potenti
technolog
similarli
appli
dna
vaccin
design
vaccin
applic
may
import
longterm
tissu
antigen
express
achiev
use
retroviru
system
high
transduct
effici
integr
rate
unfortun
case
leukemia
dave
et
al
result
random
integr
therapeut
retroviru
vector
episomallymaintain
vector
util
scaffoldmatrix
attach
region
smar
develop
potenti
substitut
cones
et
al
vector
includ
epsteinbarr
viru
ebv
orip
element
maintain
selfrepl
singl
administr
transgen
shown
express
mous
tissu
least
month
argyro
et
al
minicircl
dna
technolog
also
appli
episom
vector
higher
sustain
vitro
vivo
mous
model
transgen
express
achiev
sever
month
absenc
select
argyro
et
al
suggest
system
could
appli
vaccin
design
prolong
antigen
express
discuss
immun
respons
induc
dna
vaccin
may
various
mediat
antigen
present
transfect
somat
cell
transfect
profession
apc
crosspresent
antigen
apc
ingest
apoptot
transfect
cell
abil
nonprofession
apc
present
antigen
mhc
class
ii
pathway
therebi
induc
helper
cell
limit
strategi
therefor
develop
target
dna
vaccin
profession
apc
dc
skin
mucos
tissu
lymph
node
contain
dc
muscl
thu
use
tissu
target
dc
lymph
node
target
vector
creat
design
plasmid
encod
human
igg
fuse
either
lselectin
cytotox
tlymphocyt
antigen
lselectin
facilit
target
lymph
node
bind
endotheli
cell
target
express
antigen
apc
express
target
strategi
enhanc
immun
respons
recent
studi
hantaan
viru
htnv
nucleocapsid
protein
fuse
produc
htnv
dna
vaccin
mous
model
pig
studi
increas
vaccin
immunogen
obtain
fusion
asfv
antigen
singl
chain
antibodi
variabl
region
swine
hlaii
mani
dc
target
method
success
use
mous
model
target
molecul
fire
receptor
cire
ctype
lectin
receptor
synthet
mhc
class
iitarget
peptid
corbett
et
al
daftarian
et
al
kataoka
et
al
lahoud
et
al
njongmeta
et
al
target
method
differ
regard
effect
exampl
effect
target
induct
cytotox
lymphocyt
ctl
respons
shown
enhanc
antibodi
product
lahoud
et
al
dna
vaccin
target
fire
cire
appear
need
danger
signal
adjuv
elicit
robust
immun
respons
corbett
et
al
lahoud
et
al
special
design
synthet
materi
help
target
plasmid
profession
apc
exampl
pdnalipoplex
engraft
flagellinderiv
peptid
abl
target
plasmid
dc
apc
mous
subcellular
target
anoth
strategi
enhanc
plasmidencod
antigen
process
andor
present
strategi
use
host
protein
traffick
mechan
target
express
protein
particular
cellular
compart
mark
secret
therebi
facilit
antigen
process
present
one
wide
use
signal
sequenc
subcellular
target
lysosom
associ
membran
protein
earli
studi
fuse
human
papillomaviru
type
dna
gener
chimer
dna
vaccin
target
hpv
antigen
endosom
compart
therebi
enhanc
immunogen
dna
vaccin
lamp
target
system
subsequ
shown
effect
mani
differ
model
system
de
arruda
et
al
lu
et
al
marqu
et
al
rigato
et
al
yang
et
al
lamp
sequenc
also
combin
signal
sequenc
exampl
protect
antigen
bacillu
anthraci
fuse
tissu
plasminogen
activ
gener
shown
induc
high
neutral
antibodi
titer
anthrax
midha
bhatnagar
ubiquitin
human
tail
sequenc
also
test
dna
vaccin
target
sequenc
niazi
et
al
wang
et
al
target
strategi
infal
howev
hepat
c
viru
core
protein
vaccin
enhanc
fusion
ubiquitin
vidalin
et
al
rabi
dna
vaccin
similarli
show
benefit
mhc
class
ii
target
sequenc
recent
studi
compar
differ
target
sequenc
includ
secret
signal
endoplasm
reticulum
adenoviru
signal
fuse
green
fluoresc
protein
gfp
tag
model
gene
invari
surfac
glycoprotein
transsialidas
trypanosoma
brucei
differ
express
gene
effect
cellular
target
vari
studi
intracellular
transport
fate
plasmid
dna
mammalian
cell
show
plasmid
endocytosi
alter
ph
valu
late
endosom
therebi
interfer
antigen
process
trombon
et
al
thu
differ
antigen
fuse
lysosom
target
sequenc
physic
chemic
properti
nonhost
protein
may
interfer
normal
endosom
function
address
problem
understand
molecular
pathway
plasmidexpress
antigen
need
recent
progress
shown
import
autophagi
pathway
process
munz
rapamycininduc
autophagi
shown
enhanc
present
mycobacteri
antigen
inhibit
autophagi
rnai
attenu
present
jagannath
et
al
similarli
short
polypeptid
herp
simplex
viru
type
gene
induc
antigen
aggreg
autophagosom
degrad
enhanc
cell
respons
coexpress
chicken
ovalbumin
fu
et
al
anoth
subcellular
target
method
involv
inclus
leader
sequenc
local
signal
dna
allow
direct
local
antigen
membran
secret
outsid
cell
forn
et
al
found
membranebound
secret
form
hcv
dna
vaccin
induc
antibodi
compar
intracellular
form
et
al
dna
vaccin
need
get
nucleu
transcript
strategi
nuclear
target
includ
liposom
small
peptid
use
nuclear
local
signal
nl
also
use
increas
antigen
express
wang
et
al
vaccin
adjuv
function
rang
mechan
includ
innat
immun
activ
antigen
depot
format
chemotaxi
antigen
uptak
present
profession
apc
upregul
costimulatori
molecul
convent
vaccin
adjuv
includ
alum
particl
khosroshahi
et
al
emuls
ott
et
al
mix
plasmid
also
shown
modesti
improv
immunogen
dna
vaccin
cpg
oligonucleotid
activ
also
use
dna
vaccin
adjuv
bode
et
al
anoth
place
adjuv
may
relev
dna
primeprotein
boost
context
adjuv
combin
protein
boost
magnifi
immun
respons
induc
dna
prime
exampl
polysaccharid
nanoparticl
adjuv
success
combin
hiv
envelop
protein
boost
enhanc
immunogen
envencod
dna
vaccin
cristillo
et
al
lobig
et
al
petrovski
petrovski
petrovski
cooper
given
dna
vaccin
easili
design
express
cytokin
costimulatori
molecul
nucleic
acid
sequenc
per
se
may
serv
agonist
cellular
dna
sensor
dna
vaccin
design
coexpress
call
genet
adjuv
molecul
genet
adjuv
includ
cytokin
chemokin
immun
stimulatori
molecul
express
plasmid
dna
ci
tran
use
genet
adjuv
enhanc
dna
vaccin
immunogen
recent
extens
review
henc
wo
nt
cover
detail
saad
petrovski
tovey
lallemand
addit
well
character
genet
adjuv
molecul
strategi
enhanc
dna
vaccin
manipul
molecular
level
could
also
provid
adjuv
effect
exampl
mhc
ciita
critic
regul
mhc
class
ii
express
coadministr
dna
ciita
dna
result
enhanc
antigenspecif
cell
respons
mous
model
kim
et
al
retino
acidinduc
gene
rigi
import
cellular
receptor
dsrna
rigi
agonist
express
rna
polymeras
iii
promot
enhanc
hemagglutininspecif
antibodi
avid
intramuscular
inject
influenza
dna
vaccin
mice
luke
et
al
recent
studi
found
upon
dsrna
viral
infect
mitochondri
protein
mav
form
prionlik
aggreg
activ
hou
et
al
suggest
manipul
mav
conform
chang
deliveri
dna
vaccin
develop
new
aggreg
form
polypeptid
may
success
increas
dna
vaccin
immunogen
studi
also
use
decoy
system
fuse
antigen
viral
dnajlik
sequenc
j
domain
associ
constitut
express
host
cell
stress
protein
heat
shock
protein
system
support
effici
protein
express
includ
unstabl
andor
toxic
antigen
riedl
et
al
schirmbeck
et
al
anoth
issu
dna
vaccin
efficaci
mode
deliveri
standard
intramuscular
inject
nake
dna
ineffici
tini
fraction
inject
dna
taken
cell
express
altern
method
inject
dna
vaccin
coat
nanoor
microparticl
protect
plasmid
degrad
increas
phagocyt
uptak
profession
apc
xiang
et
al
plasmid
dna
also
coat
colloid
gold
particl
deliv
gene
gun
method
although
one
advantag
gene
gun
target
langerhan
cell
profession
apc
porgador
et
al
stoeckling
et
al
limit
dose
capac
mean
multipl
shot
multipl
site
need
effect
immun
howev
signific
improv
deliveri
dna
vaccin
electropor
ep
ep
effici
transfect
somat
cell
vivo
induct
local
inflamm
also
enhanc
immun
respons
clinic
trial
confirm
efficaci
ep
van
drunen
littelvan
den
hurk
hannaman
exampl
ep
hepat
b
viru
hbv
dna
induc
potent
ctl
respons
mice
rabbit
luxembourg
et
al
ep
similarli
enhanc
humor
respons
dhbv
dna
vaccin
duck
khawaja
et
al
ep
also
shown
enhanc
immunogen
mice
dna
coat
microparticl
barbon
et
al
ep
therefor
remain
promis
approach
improv
immunogen
dna
vaccin
although
poor
toler
ep
remain
concern
prophylact
vaccin
set
sardesai
weiner
epigenet
studi
herit
mechan
affect
transcript
state
gene
due
chang
dna
sequenc
epigenet
mechan
includ
histon
modif
variant
dna
methyl
chromatin
remodel
rnai
noncod
rna
epigenet
shown
involv
wide
varieti
biolog
process
includ
immun
system
function
cuddapah
et
al
goldberg
et
al
epigenet
tool
may
use
unravel
dna
vaccin
mechan
design
potent
dna
vaccin
studi
adenovirusvector
mediat
gene
deliveri
rat
given
intramuscular
inject
viru
express
human
fibroblast
growth
factor
driven
cmv
promot
ratio
copi
mrna
per
copi
viral
dna
decreas
hour
day
inject
extens
methyl
cmv
shown
respons
gene
silenc
brook
et
al
gene
express
use
plasmid
dna
face
similar
silenc
effect
suggest
enhanc
antigen
express
could
achiev
silenc
effect
avoid
sequenc
episom
vector
origin
bacteri
sourc
play
critic
role
transcript
silenc
transgen
vivo
riu
et
al
furthermor
episom
vector
undergo
chromatin
vivo
persist
silenc
transgen
express
associ
specif
histon
modif
remov
bacteri
element
use
minicircl
dna
technolog
enabl
higher
transgen
express
manifest
activ
histon
mark
detect
chip
assay
riu
et
al
indic
plasmid
locat
within
nucleu
epigenet
regul
transcript
take
place
studi
cancer
vaccin
confirm
modulatori
agent
includ
dna
methyltransferas
dnmt
histon
deacetylas
hdac
inhibitor
enhanc
antigen
mhc
class
express
karpf
anoth
studi
found
activ
histon
modif
hdac
inhibitor
enhanc
effect
receptor
target
immunotoxin
murin
model
human
pancreat
cancer
fujisawa
et
al
studi
parasit
infect
found
dnaprotein
complex
requir
entri
parasit
dna
cell
recognit
nucleosom
histonedna
complex
confirm
immunostimulatori
compon
plasmodium
falciparum
activ
dc
gowda
et
al
anoth
studi
found
histon
releas
tissu
injuri
mediat
cell
death
activ
thu
plasmid
dna
may
reconstitut
histon
bear
activ
modif
achiev
higher
antigen
express
increas
dna
vaccin
immunogen
cell
critic
control
viral
infect
epigenet
mechan
involv
activ
cell
mainten
memori
cell
ident
pearc
shen
youngblood
et
al
may
also
util
dna
vaccin
design
fernandezmorera
et
al
rna
interfer
rnai
posttranscript
gene
silenc
process
trigger
doublestrand
short
hairpin
rna
shrna
structur
sinc
discoveri
rnai
mainli
use
research
tool
loss
function
studi
target
gene
also
therapeut
method
human
diseas
lare
et
al
due
eas
product
flexibl
deliveri
rnai
technolog
potenti
applic
dna
vaccin
design
one
way
use
rnai
dna
vaccin
would
use
block
gene
suppress
vaccin
action
exampl
immun
respons
induc
dna
vaccin
attenu
due
limit
durat
antigen
express
vivo
due
death
transfect
cell
use
shrna
knock
caspas
cell
death
mediat
upregul
dna
vaccin
result
increas
plasmid
luciferas
env
antigen
express
higher
cell
antibodi
product
geibenlynn
et
al
similarli
rnaimedi
deplet
proapoptot
protein
bak
bax
time
immun
vaccin
prolong
life
antigenexpress
dc
increas
antitumor
effect
tumor
kim
et
al
fasmedi
apoptosi
limit
dna
vaccineinduc
immun
respons
greenland
et
al
codeliveri
dna
vaccin
dna
express
shrna
fa
ligand
significantli
enhanc
ctl
respons
huang
et
al
rnai
may
also
use
block
immunesuppress
gene
otherwis
inhibit
vaccin
respons
deplet
critic
suppress
regul
cell
prolifer
rnai
increas
efficaci
dna
cancer
vaccin
wang
et
al
similarli
knockdown
receptor
enhanc
potenc
dc
vaccin
kim
et
al
furthermor
blockad
program
cell
ligand
rnai
augment
dcmediat
cell
respons
antivir
immun
hbv
transgen
mice
jiang
thu
use
rnai
target
gene
limit
plasmid
express
apoptosi
gene
mediat
immun
suppress
effect
power
new
strategi
dna
vaccin
enhanc
howev
safeti
issu
use
rnai
enhanc
human
dna
vaccin
still
need
address
henc
technolog
like
first
appli
therapeut
cancer
vaccin
rather
typic
prophylact
vaccin
acceler
advanc
nextgener
sequenc
microarray
high
throughput
proteom
approach
provid
opportun
appli
new
techniqu
dna
vaccin
design
one
recent
proteom
studi
screen
protein
interact
plasmid
dna
found
human
serum
amyloid
p
sap
inhibit
plasmid
transfect
enhanc
plasmid
clearanc
sap
may
contribut
low
efficaci
dna
vaccin
human
speci
suppress
effect
sap
much
weaker
wang
et
al
henc
sap
could
exampl
serv
new
sirna
target
enhanc
dna
vaccin
efficaci
although
feasibl
effect
safeti
approach
would
first
need
test
suitabl
anim
model
system
biolog
approach
also
use
analyz
molecular
signatur
correl
posit
immun
respons
exampl
express
level
camkiv
kinas
day
neg
correl
subsequ
influenza
antibodi
titer
nakaya
et
al
provid
success
exampl
applic
system
biolog
identifi
biomark
predict
vaccin
effect
trautmann
sekali
studi
leptospira
interrogan
use
bioinformat
compar
genom
hybrid
transcript
analysi
screen
candid
antigen
pathogen
genom
found
candid
gene
open
read
frame
orf
yang
et
al
concept
revers
vaccinolog
sett
rappuoli
ribosom
display
cryptosporidium
parvum
cdna
librari
enabl
identif
new
adhes
protein
name
includ
dna
vaccin
induc
antibodi
cellular
respons
protect
xiao
et
al
sinc
dna
vaccin
quick
easi
prepar
particularli
use
screen
potenti
antigen
identifi
revers
vaccinolog
approach
thu
develop
new
dna
vaccin
futur
assist
next
gener
sequenc
advanc
bioinformat
analysi
cuttingedg
omic
technolog
poland
et
al
whilst
dna
vaccin
suffer
low
immunogen
necessarili
true
combin
vaccin
modal
primeboost
type
approach
regimen
like
dna
primeprotein
boost
dna
primevir
vector
boost
eg
use
adenoviru
shown
major
success
earli
studi
mous
model
shown
dna
prime
follow
singl
protein
boost
modifi
vaccinia
viru
ankara
mva
antigen
induc
complet
protect
challeng
correl
induct
high
level
cell
schneider
et
al
mous
studi
leishmania
donovani
vaccin
compar
differ
primeboost
combin
found
dna
primeprotein
boost
regimen
better
dnadna
proteinprotein
regimen
longterm
protect
mous
model
mazumd
et
al
human
studi
also
shown
superior
immun
respons
mix
modal
primeboost
compar
pure
dna
vaccin
regimen
lu
et
al
recent
studi
use
dnaprotein
dnaadvector
regimen
hiv
immun
churchyard
et
al
de
rosa
et
al
jaoko
et
al
koblin
et
al
ledgerwood
et
al
underli
mechan
behind
effect
heterogen
primeboost
regimen
well
understood
dna
prime
result
much
lower
antigen
express
compar
protein
vaccin
may
preferenti
prime
thelper
cell
respons
humor
respons
subsequ
boost
high
dose
protein
viral
vector
boost
immunogen
dna
vaccin
human
limit
low
level
antigen
express
compar
convent
protein
vaccin
dna
vaccin
may
abl
make
limit
alter
plasmid
construct
maxim
protein
express
target
express
antigen
profession
apc
therebi
ensur
effici
mhci
mhcii
compart
load
inclus
genet
adjuv
use
electropor
suitabl
use
dna
primeprotein
vector
boost
approach
summar
figur
develop
new
technolog
provid
even
greater
opportun
enhanc
efficaci
dna
vaccin
like
scenario
first
success
human
dna
vaccin
part
dna
primeprotein
boost
vaccin
strategi
initi
dna
prime
use
ensur
effici
tcell
prime
wherea
protein
boost
use
maxim
antibodi
product
notabl
twenti
year
initi
discoveri
mani
disappoint
human
clinic
trial
first
gener
vaccin
dna
vaccin
current
undergo
somewhat
reviv
thank
introduct
effici
design
better
deliveri
technolog
includ
electropor
mani
outsid
field
may
still
right
skeptic
given
failur
meet
earli
promis
uncommon
phase
new
technolog
introduct
often
herald
final
success
reminisc
histori
monoclon
antibodi
therapeut
similarli
went
highli
neg
phase
initi
technolog
problem
solv
emerg
pharmaceut
blockbust
dna
vaccin
may
similarli
move
past
darkest
hour
therebi
soon
readi
reemerg
commerci
viabl
product
like
initi
area
therapeut
cancer
vaccin
literatur
referenc
review
search
use
pubm
databas
literatur
publish
prior
march
keyword
dna
vaccin
dna
vaccin
dna
vaccin
dna
vaccin
dna
immun
dna
immun
gene
vaccin
gene
vaccin
genet
vaccin
alon
along
relat
topic
eg
epigenet
rnai
studi
publish
recent
two
year
paid
attent
repres
date
develop
area
overview
strength
weak
previou
dna
vaccin
optim
strategi
identifi
new
technolog
smar
vector
mcdna
rnai
relev
dna
vaccin
design
epigenet
omic
technolog
provid
excit
new
opportun
immin
breakthrough
human
dna
vaccin
incorpor
latest
technolog
recent
studi
found
dispens
dna
vaccin
pathway
shown
critic
plasmid
dna
induc
innat
adapt
immun
respons
howev
upstream
bona
fide
b
dna
sensor
still
remain
unknown
eas
dna
synthesi
manipul
lot
high
throughput
technolog
eg
gene
express
array
proteom
genom
transcriptom
revers
vaccinolog
rnai
screen
platform
accompani
comprehens
bioinformat
tool
effici
map
find
dna
sequenc
encod
optim
antigen
vaccin
develop
b
select
candid
pathogen
dna
sequenc
codon
optim
promot
design
main
two
step
clone
express
vector
simpl
codon
convers
use
strong
viral
promot
like
result
higher
gene
express
controversi
effect
also
report
precis
algorithm
anticip
purpos
field
plasmid
dna
base
therapi
vaccin
c
optim
dna
fragment
clone
express
vector
test
express
optim
dna
vaccin
minicircl
dna
technolog
use
complet
remov
bacteri
element
incorpor
smar
sequenc
e
enhanc
express
safeti
f
g
epigenet
mechan
close
relat
step
appli
dna
vaccin
design
h
immunogen
dna
vaccin
construct
could
increas
inject
optim
construct
use
new
deliveri
devic
eg
ep
andor
use
primeboost
regimen
see
articl
detail
